Alliance Pharma PLC Director Shareholding (8873N)

TIDMAPH

RNS Number : 8873N

Alliance Pharma PLC

23 January 2019

 
                                               23 January 2019 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director Shareholding

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified on 22 January 2019 that on 22 January 2019 Richard Jones, a Non-Executive Director of the Company, purchased 15,000 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 65.28 pence per share.

Following this transaction, Mr Jones' total beneficial interest in the Company is 15,000 Ordinary Shares, representing less than 0.01% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                    Richard Jones 
      --------------------------------------  ---------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------------- 
 a)    Position/status                         Non-Executive Director 
      --------------------------------------  ---------------------------------- 
 b)    Initial notification                    Initial Notification 
        /Amendment 
      --------------------------------------  ---------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------- 
 a)    Name                                    Alliance Pharma Plc 
      --------------------------------------  ---------------------------------- 
 b)    Legal Entity                            213800RYIWZA4Q5WPZ13 
        Identifier 
      --------------------------------------  ---------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------------- 
 a)    Description                             Ordinary shares of 1 pence each 
        of the financial 
        instrument,                             GB0031030819 
        type of instrument 
 
        Identification 
        code 
      --------------------------------------  ---------------------------------- 
 b)    Nature of                               Purchase of shares 
        the transaction 
      --------------------------------------  ---------------------------------- 
 c)    Currency                                GBP 
      --------------------------------------  ---------------------------------- 
 d)    Price(s)                                   Price(s)         Volume(s) 
        and volume(s) 
      --------------------------------------  ---------------  ----------------- 
                                                   65.28p            15,000 
 -------------------------------------------  ---------------  ----------------- 
 
 e)    Aggregated 
        information                              n/a 
        - Aggregated 
        volume 
        - Price 
        - Aggregated 
        total 
      --------------------------------------  ---------------------------------- 
 f)    Date of the                             22 January 2019 
        transaction 
      --------------------------------------  ---------------------------------- 
 g)    Place of                                London Stock Exchange, AIM 
        the transaction 
      --------------------------------------  ---------------------------------- 
 

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Michael Meade / 
  Freddie Barnfield 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                    + 44 (0)20 7597 5970 
 Corporate Finance: Daniel Adams / 
  Ed Thomas 
 Corporate Broking: Patrick Robb / 
  David Herring 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHUORRRKOAAUAR

(END) Dow Jones Newswires

January 23, 2019 05:06 ET (10:06 GMT)